Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lemzoparlimab - AbbVie/I-MAb Biopharma

X
Drug Profile

Lemzoparlimab - AbbVie/I-MAb Biopharma

Alternative Names: ABBV-IMAB-TJC4; Anti-CD47 antibody - I-Mab; TJ-011133; TJ-1133; TJC-4

Latest Information Update: 08 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator I-MAB Biopharma
  • Developer AbbVie; I-MAB Biopharma
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myelodysplastic syndromes
  • Phase II Acute myeloid leukaemia; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer
  • Phase I/II Solid tumours
  • Phase I Multiple myeloma

Most Recent Events

  • 23 Feb 2024 Abbvie terminates phase Ib trial in Myelodysplastic syndromes and Acute myeloid leukaemia (Combination therapy, First-line therapy) in USA, Israel, Australia, Germany, Italy, Japan, Spain, United Kingdom (IV, Infusion), due to strategic considerations (NCT04912063) (EudraCT2021-000514-41)
  • 15 Dec 2023 I-Mab Biopharma completes a phase I/II trial in Acute myeloid leukaemia and Myelodysplastic syndromes (Combination therapy, Newly diagnosed, Second-line therapy or greater) (Parenteral) in China (NCT04202003)
  • 09 May 2023 Abbvie completes phase Ib trial in Myelodysplastic syndromes and Acute myeloid leukaemia (Combination therapy, First-line therapy) in USA, Israel, Australia, Germany, Italy, Japan, Spain, United Kingdom(IV) (NCT04912063) (EudraCT2021-000514-41)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top